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“To be trusted is a greater compliment than to be loved.” effort, with remarkable strides being made in pharmaceutical
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thics and their direct corollary—conflicts of interest (COI)—
re again dominating medical discussions. Entities of all
tripes, from the National Institutes of Health (NIH) to
laxoSmithKline to our peer Journal of the American Medical
ssociation, are being attacked for being less than forthcoming
1). There is an endless stream of allegations from the media
hat research organizations and health care professionals are
ntentionally “hiding” influential connections or negative re-
ults, culminating in destruction of the public trust and a
ervasive perception of physician self-interest (2).
Even prominent medical professionals are pointing fin-
ers, claiming in editorials that the use of “heavily conflicted
xperts” by medical organizations to make clinical policy
erodes the confidence of the public” (3). Although such
ccusations are most often not grounded in fact but in
upposition, the American College of Cardiology (ACC)
till must take such attitudes seriously. We must uphold the
anctity of the health care professionals’ role, which requires
he public’s trust in order to be effective in our work.
The trust-based doctor-patient relationship is sacrosanct
n our society. Not only is it the hallmark of good medicine
ut it is also legally protected. Patients must intentionally
aive their inalienable doctor-patient privacy rights under
he Health Insurance Portability and Accountability Act
HIPAA) so as to empower their physicians to breach this
rust. Today’s rapidly evolving medical environment, how-
ver, can create illusory Hobson’s choices where the inter-
sts of the physician and the patient can appear to be
ontradictory. In fact, there is little room for choice. Ethical
ecisions keeping the patient primary must be made in all
nstances, and the physician must be prepared to understand
nd manage the repercussions of those actions.
Clinician-scientists and the medical industry continually
evelop new methods to support patients living with cardio-
ascular disease. Society has benefited from this methodicalm
*Throughout his Presidential year, Dr. Wolk will present ideas important to
ollege members, in collaboration with key ACC leaders and staff.nd medical device solutions. We also have witnessed—and
riven—a change in culture that encourages heart-healthy
abits, such as reduced smoking and weight consciousness.
atient-care protocols have improved worldwide through
lobal cooperation, and lives are being saved.
As we know all too well, however, more—and better—
reatment options can lead to thorny ethical issues. Access to
utting-edge care for certain populations can create perceived
nequities in treatment. Patient-participants in research pose a
eculiar dilemma for doctor-investigators seeking to treat
isease yet advance knowledge. Researchers may engage in
elationships with industry that they consider perfectly harm-
ess but that can appear to present inescapable COI. Any of
hese circumstances can result in perceived harm to our primary
oncern, the patient. Harm, in this sense, may manifest as a
hysical detriment, or it may be a deterioration—or destruc-
ion—of the patient’s faith. Such a situation automatically
reaches the hallowed physician-patient trust relationship that
s fundamental to an effective health care environment.
Perception, however, should not be automatically inferred as
eality. In our ACC members’ daily practices, protecting
atients’ rights and trust is de rigueur. Cardiovascular special-
sts are renowned, with very few exceptions, for keeping their
atients’ best interests at heart when creating care protocols or
ecommending life-management strategies. Rather than as-
uming the worst about physicians when it comes to potential
OI, we submit it is far more accurate to assume the best.
High-profile cases in the media, however, have negatively
rained the spotlight on ethics and the issue of COI. The
IH, through its subsidiary National Heart, Lung, and
lood Institute, released the National Cholesterol Educa-
ion Program Update in July of this year, and unintention-
lly created a furor by failing to publish author disclosure of
ies to affected industry (4). This contretemps came on the
eels of an ongoing media frenzy that erupted in the spring
ver GlaxoSmithKline’s management of its Paxil antide-
ressant studies related to children and adolescents (5).
This exceptionally sensitive COI climate reinforces the
CC’s position that there is no room for conjecture here. We
ust adopt bright-line ethical guides that remain flexible
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e are using COI management in the broadest sense here,
ncompassing clinical trial procedures, patient-participant pro-
urement, industry and physician-investigator financial deal-
ngs, efficacy of findings in industry-sponsored tests, disclosure
f all physician benefits derived from dealings with industry,
nd self-made patient testing referrals.
The first step toward providing advice and direction for
ll cardiovascular care professionals is to identify problem-
rone situations and to expose them to vigorous, open, and
olution-focused dialogue. Although frankly discussing our
rofessional ethical challenges may generate anxiety among
he lay public and the press, we firmly believe the first step
o setting strong standards for uniform and optimal behav-
or for ourselves and our colleagues is to thoroughly examine
reas we consider cause for concern.
As a major thought leader for cardiovascular care, the ACC
s compelled to offer direction and guidance to its 31,500
embers worldwide. We take this responsibility very seriously,
s we hold ourselves before the mirror before others feel
mpowered to control our actions through legislation or
egulation (6). Establishing acceptable choices is our charge,
nd we must all have the courage to challenge ourselves and
ach other to attain and maintain unassailable ethical reputa-
ions through bullet-proof behavior.
To this end, the American College of Cardiology Founda-
ion (ACCF) and the American Heart Association (AHA)
onvened a June 2004 Bethesda Consensus Conference on
rofessionalism and Ethics. Since the last Bethesda conference
n ethics in 1999, significant advances have occurred in
ardiovascular medicine. Although consensus recommenda-
ions from this joint ACCF/AHA conference do not consti-
ute organizational policy, we sincerely hope they will be
dopted by both organizations, resulting in common principles
or cardiovascular specialists.
Six task forces tackled tough topics ranging from procur-
ng patients for human-subjects research to prescribing tests
o be performed by the same physician. These task forces
id not shy away from confronting difficult discussions.
ather, they embraced the issues and debated their merits
nd demerits. The resulting document, which is published
n toto this issue of the Journal of the American College of
ardiology (JACC), touches on research methodology, COI
isclosure, and fiduciary duty.
When physicians deal with human subjects in research,
here are basic ethical principles, articulated in the Belmont
eport of 1979 (7), stemming from the Tuskegee Syphilis
tudy. Human participant research is a crucial element in the
evelopment and approval of new drugs, biologics, devices, and
rocedures that seek to improve patient care. Participation in
linical research is an important professional obligation for
ardiovascular practitioners. This involvement ranges from
tudy design and implementation as investigators to the critical
ole of subject enrollment for all cardiovascular practitioners: eUnderrepresented groups in clinical trials (elderly, women,
ethnic minorities) need to be actively recruited and included
in studies
Investigators must fully disclose financial and any other type
of COI to potential subjects
Institutional review boards should have two processes, one to
monitor patient safety and another to deal with COI
Physician-investigators should be fully involved in the design
and conduct of the trial, including maintaining responsibility
for reporting results
All trial results should be reported without undue delay, not
just trials that are positive
A publications committee should be established for multi-
center studies prior to the start of the study and should
prevent control of the publication process either by the
sponsor or by a single investigator
Pharmaceutical clinical trials can create a difficult dichot-
my for physician-investigators. When the world’s best
esearcher-physicians are recruited to perform and analyze
mportant drug trials, they are damned if they do and
amned if they do not. This conundrum has been eased
omewhat by the laudable actions of several pharmaceutical
ompanies to publicly disclose results from all clinical trials
8). In the interest of corporate responsibility and transpar-
ncy, such a free registry is the only sound option.
Disclosure of potential COI should be made for all ACC
nd AHA activities, without exception. Specific financial
riteria are proposed by the Conference Task Force, in
ddition to documenting other non-tangible benefits doc-
ors may derive from interactions with industry. Both the
CC and the AHA should adopt a single COI policy and
orm, and both organizations should maintain a secure and
niform database of COI, one that is updated regularly.
In practice, we reaffirm our stringent JACC disclosure
equirements. Our basic policy is to offer all relevant
elationships to readers, then let readers interpret the data in
his light. All submissions must be accompanied by full-
isclosure documents, which are formally attested to by the
nvestigators. Likewise, peer reviewers must supply a com-
lete list of industry relationships (9). This cross-check
erves to ensure that evaluation of the study is not subjected
o bias. While not every reviewer who carries a potential
OI is omitted, we do seriously consider each such circum-
tance. Although JACC occasionally publishes manuscripts
uthored by individuals from industry, we never accept such
ieces as state-of-the-art reviews.
In addition, JACC’s policy has been to publish important
egative research results. Although we recognize a negative
esult often is considered less important and less likely to be
ited in future studies, we believe making such results public
s a valuable professional and public service. In a similar
ein, we sometimes will ask contributors to provide addi-
ional data that we have determined should be available,
ven if it has been omitted from the initial manuscript.
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October 19, 2004:1709–11 President’s PageRegarding research protocols and patient-participant in-
ormed consent, JACC again assumes a tough stand. Editors
ake note of how each manuscript fulfills the general
equirements of institutional approval for protocol and
nformed consent. Occasionally, we have declined to publish
anuscripts that did not provide evidence that these fun-
amental processes were appropriately conducted.
These strong policies also hold true for presenters of ab-
tracts and posters at our renowned Annual Scientific Session
nd also for those who participate in the clinical guidelines for
orking groups. Participating professionals must meet an
xceptional standard of disclosure, both in writing and verbally,
uring the presentations (10). Our Annual Scientific Session
raws more than 400 media from around the world, creating
ast-paced delivery of data to both the lay and trade press. Such
uick dissemination demands a cadre of presenters who meet
ur ethics standards, and it requires the ACC to be diligent in
redentialing them.
Another sticky potential COI is the practice of the same
hysician ordering and then performing in-office tests on his or
er patients. Such circumstances are becoming increasingly
ommon as well-trained cardiovascular practices appropriately
ncorporate emerging technology in their facilities. Although
his decision typically is made to provide the most efficient and
ffective medical management of each patient, it poses a
otential perception of COI and requires our close vigilance.
he ACCF/AHA guidelines are an especially important
echanism to assure accepted evidence-based “best practices”
tandards of care and avoid inappropriate self-referral (11).
Heart hospitals, for example, may offer attractive advan-
ages for consolidated patient care, but they also can open
he door to charges of COI. Cardiologists must be exceed-
ngly careful when it comes to investing in such facilities.
he ACC and the AHA, as well as governmental agencies,
hould continue to collect data and monitor activity and
utcomes in free-standing cardiovascular care centers that
ave close ties to cardiovascular practice groups.
Likewise, direct-to-consumer advertising is totally unregu-
ated when applied to cardiovascular services. Misinformation,
ntentional or otherwise, can be deadly for our vulnerable and
ften-fragile patients. Methods should be devised to examine
nd control the veracity of information given to consumers,
nd consequences must be established for practitioners who
iolate the public trust with misleading or untruthful materials.
Cardiovascular specialists, in fact, have an obligation to
erve as objective, third-party experts to the public, be it
hrough the lay press or in the courtroom. Malpractice
itigation poses special challenges for cardiovascular special-f responding to this call because expert witness testimony
s, effectively, part of medical practice. Our goal on the stand
hould be to objectively educate those individuals in the case
nd should be independent of the attorneys paying for our
pinion. The physician expert also should be board certified
n areas in which he or she is asked to testify, erasing any
uestion about preparation or ability to represent the very
est in cardiovascular care.
These many issues, in congregate, may appear to hopelessly
uddle our pursuit of a guiding “bright line” for making ethical
hoices. The “grays” may appear to overwhelm the black-and-
hite of clear choice. Quite the contrary, professional ethics
equires our moral obligation to do what is good and honorable
or our patients, for each other, and for society. When patients
re the first consideration in all things, ethical dilemmas shrink
recipitously and physician self-interest cannot be a deciding
actor. After all, patients come to us for care “without fear or
isgiving.” They rely upon us to be providers of sound
edicine on their behalf, and they believe we will shelter them.
s always, our Hippocratic Oath is our ethical guide. First, do
o harm.
end correspondence to: Dr. Michael J. Wolk, 520 East 72nd
treet, New York, New York 10021.
EFERENCES
1. Martinez B, Windham C. Pfizer finds two failed trials equal one coup
for Zoloft. The Wall Street Journal, August 6, 2004:B1.
2. Willman D. Stealth merger: drug companies and government medical
research. Los Angeles Times, December 7, 2003:A1.
3. Kassirer J. Why should we swallow what these studies say? The
Washington Post, August 1, 2004:B3.
4. Johnson L. Groups blast new cholesterol guidelines over conflict of
interest. Detroit News, July 17, 2004. Available at: www.detnews.com.
Accessed August 15, 2004.
5. Meier B. Medicine’s data gap: selective disclosure; two studies, two
results, and a debate over a drug. The New York Times, June 3, 2004:
C1,2.
6. Henderson JA, Smith JJ. Financial conflict of interest in medical
research: overview and analysis of federal and state controls. Food
Drug Law J 2002;57:445–56.
7. Gross CP. Financial conflict of interest and medical research: beware
the medical-industrial complex. J P Sci Law 2001;1.
8. One firm’s bold step helps doctors, patients avoid errors. USA Today,
August 10, 2004:10A.
9. Journal of the American College of Cardiology Author Information:
Conflict of Interest Policy. http://www.cardiosource.com/library/
journals/journal/Authorinfo?sdid4884. Accessed August 15, 2004.
0. American College of Cardiology Annual Scientific Session 2005: Abstract
and Speaker Information. http://www.acc.org/2005ann_meeting/
abstract/abstract.htm#disclosure. Accessed August 15, 2004.
1. Wolk MJ, Peterson E, Brindis R, Eagle K. The appropriate cardiol-
ogist: responsible stewardship in a golden era of cardiology. J Am Collsts who are requested to testify. Each of us bears the burden Cardiol 2004;44:933–5.
ACC ‘05: Bridging Science and Practice
Registration for the 54th Annual Scientific Session opens September 16!
Plan to join your fellow cardiologists in Orlando, Florida, March 6–9, 2005 for
exceptional science and clinical applications. For more information, go to www.acc.org.
